Ipamorelin

The scientific literature on ipamorelin is primarily composed of review articles published in 2026 that discuss peptide therapies broadly rather than specific clinical studies on ipamorelin itself. These reviews examine ipamorelin within the context of growth hormone-releasing peptides and their applications across several medical fields.

Multiple review papers have addressed ipamorelin's role in sports medicine and performance enhancement. Publications in JBJS Reviews, Sports Medicine, and The American Journal of Sports Medicine have examined injectable peptides including ipamorelin from safety, efficacy, and anti-doping perspectives. A critical review in The Journal of Sports Medicine and Physical Fitness specifically discussed the use of peptide drugs like ipamorelin in recreational and professional sports.

The therapeutic applications of ipamorelin have been covered in broader reviews of peptide therapies. Articles in the International Journal of Molecular Sciences and Journal of the American Academy of Orthopaedic Surgeons have discussed therapeutic peptides in aesthetic, metabolic, endocrine, and orthopedic conditions. Additionally, Frontiers in Aging published a review on therapeutic peptides in gerontology and healthy aging applications.

Important limitation: The available literature consists primarily of narrative and structured reviews rather than original research studies specifically investigating ipamorelin. These reviews do not provide detailed sample sizes, specific study designs, or individual clinical outcomes for ipamorelin, as they synthesize information across multiple peptide compounds.

Clinical Trials

Two completed Phase 2 clinical trials have specifically investigated ipamorelin:

Gastrointestinal Recovery Study (NCT01280344): This completed Phase 2 trial evaluated the safety and efficacy of ipamorelin compared to placebo for recovery of gastrointestinal function. Specific details about sample size, duration, and outcomes are not available in the provided evidence.

Post-Operative Ileus Study (NCT00672074): A second completed Phase 2 trial examined ipamorelin's safety and efficacy for managing post-operative ileus. Like the first trial, detailed study parameters and results are not provided in the available information.

Both trials focused on gastrointestinal applications rather than the growth hormone-related effects for which ipamorelin is often discussed in the literature. The limited number of completed clinical trials represents a significant gap between the clinical interest in ipamorelin reflected in review literature and the available controlled clinical evidence.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Consult with a healthcare professional before considering any peptide therapy.